|By Marketwired .||
|May 15, 2014 07:07 PM EDT||
MISSION VIEJO, CA -- (Marketwired) -- 05/15/14 -- Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three and six months ended March 31, 2014.
The Company reported a net loss of approximately $437,000, or $0.00 per share for the three months ended March 31, 2014. This compares to a net loss of $5,782,000 (including a non-cash adjustment for increases in valuation of warrants of $5,020,000), or $0.06 per share, for the three months ended March 31, 2013.
For the six months ended March 31, 2014, the Company reported a net loss of $1,132,000 or $0.01 per share. This compares to a net loss of $1,755,000 (including a non-cash adjustment for increases in valuation of warrants of $510,000) or $0.03 per share for the six months ended March 31, 2014.
"During the quarter, we continued to make significant progress towards our goal of filing a pre-Emergency Use Authorization application for AEOL 10150 as a treatment for Lung-ARS," stated John L. McManus, President and Chief Executive Officer. "We expect to complete our current study in rhesus macaque monkeys and report top line results in the third calendar quarter of this year. In addition, we will initiate a series of six mouse efficacy studies during May and June, and plan to file our IND by June as well, so that we can initiate a Phase 1 study in healthy human volunteers this fall. These initiatives, combined with our completed safety and efficacy studies, and our achievements in manufacturing under our contract with the Biomedical Advanced Research and Development Authority ("BARDA") should position us well for a pre-Emergency Use Authorization filing."
Key Accomplishments During the Quarter:
- Notice from the Office of Orphan Products Development at the U.S. Food & Drug Administration (FDA) granting Orphan Drug Designation for AEOL 10150 "for use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome." Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits.
- Data published from animal model studies and a pilot efficacy study in non-human primates (NHPs) demonstrating the efficacy of AEOL 10150 as a medical countermeasure (MCM) against the effects of radiation exposure on the lungs. Three papers on studies funded by Aeolus, grant money from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and contract money provided by BARDA were published in the journal Health Physics, volume 106, number 1, in January 2014.
- Significant progress towards developing large-scale, Good Manufacturing Practice capability for producing AEOL 10150, including:
- 90% reduction in manufacturing cost of drug substance achieved; further improvements expected upon scale up of production
- 15,000 vials of final product supplied for human safety studies to support pre-Emergency Use Authorization filing
- 18 months stability demonstrated for final drug product in new formulation at room temperature; stability testing will continue to five years.
As of March 31, 2014, the Company had approximately $520,000 in cash and cash equivalents and 134,550,068 common shares outstanding. The Company had accounts receivable of $1,839,000 and accounts payable of $2,394,000 on March 31, 2014.
On May 5, 2014, the Company executed a Modification of Contract with BARDA. The purpose of the Modification is to (1) make available $1,777,882 in reimbursement to the Company for actual costs incurred under the first three years of its contract with BARDA, (2) establish an increased provisional indirect billing rate for FY2014 and the rest of the BARDA contract period of performance, and (3) establish a cap on the indirect billing rate for the remaining contract period of performance. The Company received payment of the $1,777,882 on May 15, 2014. The effect of the Modification will be (a) to increase the cash balance of the Company and (b) to increase the billing rate for indirect costs under the contract. The Company believes the reimbursement payment and increased billing rates provide sufficient capital to fund operations for approximately two years.
Results of Operations for the Three Months Ended March 31, 2014
Revenue for the three months ended March 31, 2014 was approximately $1,438,000, versus revenue of $859,000 for the three months ended March 31, 2013. The revenue is from the contract with BARDA announced on February 11, 2011. Higher revenue in 2014 reflects both the timing of the initiation of program items as well as revenue recognition under accounting rules.
Research and development expenses increased to approximately $1,173,000 for the three months ended March 31, 2014, from approximately $618,000 for the three months ended March 31, 2013. The increase in 2014 expenses reflects both the timing of the initiation of program items under the BARDA contract as well as expense recognition under accounting rules.
General and administrative expenses were approximately $702,000 for the three months ended March 31, 2014 compared to approximately $1,003,000 for the three months ended March 31, 2014. The lower expense was primarily due to non-recurring costs related to financing in 2013.
Results of Operations for the Six Months Ended March 31, 2014
Revenue for the six months ended March 31, 2014 was approximately $2,231,000, which compares to revenue of $2,201,000 for the six months ended March 31, 2013. The revenue is from the contract with BARDA announced on February 11, 2011. Higher revenue in 2014 reflects both the timing of the initiation of program items as well as revenue recognition under accounting rules.
Research and development expenses increased to approximately $1,880,000 for the six months ended March 31, 2014, from approximately $1,787,000 for the six months ended March 31, 2013. The increase in 2014 expenses reflects both the timing of the initiation of program items under the BARDA contract as well as expense recognition under accounting rules.
General and administrative expenses were approximately $1,503,000 for the six months ended March 31, 2014 compared to approximately $1,659,000 for the six months ended March 31, 2014. The lower expense was primarily due to absence of non-recurring costs related to financing in 2013.
Corporate Update Conference Call Information
Aeolus will host a conference call on Monday, May 19th at 11:00 a.m. ET to outline the Company's achievements in the second fiscal quarter of 2014 and provide an update on the progress made to date on the BARDA contract and other biodefense development programs. Interested parties may participate by dialing (855) 644-8125 (US) or (779) 232-4780 (International), approximately five to ten minutes before the call start time. A replay of the call will be available starting on May 19, 2014, at 2:00 p.m. ET through June 19, 2014, at 11:59 p.m. ET. Interested parties may access the replay by dialing (855) 859-2056 (US) or (404) 537-3406 (International) and entering conference ID number 46809798. An archived webcast of the conference call will be available for 90 days on the Investors page of the Aeolus Pharmaceuticals web site at www.aolsrx.com.
Aeolus has filed today with the SEC its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014. Aeolus urges its investors to read this quarterly filing as well as its Annual Report on Form 10-K, also filed with the SEC, for further details concerning the Company. The Quarterly Report on Form 10-Q and the Annual Report on Form 10-K are also available on the Company's website, at www.aolsrx.com.
About AEOL 10150
AEOL 10150 is a broad-spectrum catalytic antioxidant specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure. AEOL 10150 may have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation in the treatment of oncology.
AEOL 10150 has performed well in preclinical and non-clinical studies, demonstrating statistically significant survival benefit in an acute radiation-induced lung injury model, and was well-tolerated in two human clinical trials. The Company believes it could have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation, whether from cancer therapy or a nuclear event.
About Aeolus Pharmaceuticals
Aeolus Pharmaceuticals is developing a platform of a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed, with funding by the US Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150, including the contract with BARDA valued, with options, at up to $118.4 million, to efficiently develop the compound for use in oncology. For more information, please visit Aeolus's corporate website at www.aolsrx.com.
The statements in this press release that are not purely statements of historical fact are forward-looking statements. Such statements include, but are not limited to, those relating to Aeolus' product candidates, as well as its proprietary technologies and research programs, the Company's potential initiation of large efficacy studies in mice and NHPs, as well as a phase 1 study in healthy normal volunteers, the BARDA Contract, and the expected use of proceeds from the financing. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Important factors that could cause results to differ include risks associated with uncertainties of progress and timing of clinical trials, scientific research and product development activities, difficulties or delays in development, testing, obtaining regulatory approval, the need to obtain funding for pre-clinical and clinical trials and operations, the scope and validity of intellectual property protection for Aeolus' product candidates, proprietary technologies and their uses, and competition from other biopharmaceutical companies, and whether BARDA exercises one or more additional options under the BARDA Contract. Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limited to, Aeolus' Annual Report on Form 10-K for the year ended September 30, 2013. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
AEOLUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands, except per share data) March 31, September 30, 2014 2013 ------------- ------------- ASSETS Current assets: Cash and cash equivalents $ 520 $ 869 Accounts receivable 1,839 370 Deferred subcontractor cost 1,402 656 Prepaids and other current assets 96 39 ------------- ------------- Total current assets 3,857 1,935 Investment in CPEC LLC 32 32 ------------- ------------- Total assets $ 3,889 $ 1,966 ============= ============= LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses $ 2,394 $ 579 Deferred revenue 1,458 682 ------------- ------------- Total current liabilities 3,852 1,261 ------------- ------------- Total liabilities 3,852 1,261 Commitments and Contingencies (Note F) Stockholders' equity: Preferred stock, $.01 par value per share, 10,000,000 shares authorized: Series A nonredeemable convertible preferred stock, 1,250,000 shares authorized as of March 31, 2014 and September 30, 2013, respectively; no shares issued and outstanding as of March 31, 2014 and September 30, 2013, respectively -- -- Series B nonredeemable convertible preferred stock, 1,600,000 and 1,600,000 shares authorized as of March 31, 2014 and September 30, 2013, respectively; 526,080 and 526,080 shares issued and outstanding as of March 31, 2014 and September 30, 2013, respectively 5 5 Common stock, $.01 par value per share, 200,000,000 shares authorized; 134,550,068 shares issued and outstanding as of March 31, 2014 and September 30, 2013, respectively 1,346 1,346 Additional paid-in capital 183,739 183,276 Accumulated deficit (185,053) (183,922) ------------- ------------- Total stockholders' equity 37 705 ------------- ------------- Total liabilities and stockholders' equity $ 3,889 $ 1,966 ============= =============
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
AEOLUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except per share data) Three months Ended Six Months Ended March 31, March 31, -------------------- -------------------- 2014 2013 2014 2013 --------- --------- --------- --------- Revenue: Contract Revenue $ 1,438 $ 859 $ 2,231 $ 2,201 Costs and expenses: Research and development 1,173 618 1,880 1,787 General and administrative 702 1,003 1,483 1,659 --------- --------- --------- --------- Total costs and expenses 1,875 1,621 3,363 3,446 --------- --------- --------- --------- Loss from operations (437) (762) (1,132) (1,245) Non-cash financing charges and change in fair value of warrants (Note B) -- (5,020) -- (510) --------- --------- --------- --------- Net loss $ (437) $ (5,782) $ (1,132) $ (1,755) ========= ========= ========= ========= Net loss per weighted share attributable to common stockholders: Basic (Note D) $ 0.00 $ (0.06) $ (0.01) $ (0.03) ========= ========= ========= ========= Diluted (Note D) $ 0.00 $ (0.06) $ (0.01) $ (0.03) ========= ========= ========= ========= Weighted average common shares outstanding: Basic 134,550 94,425 134,550 69,664 ========= ========= ========= ========= Diluted 134,550 94,425 134,550 69,664 ========= ========= ========= =========
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
AEOLUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (In thousands) Six Months Ended March 31, ---------------------------- 2014 2013 ------------- ------------- Cash flows from operating activities: Net loss $ (1,132) $ (1,755) Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 463 309 Change in fair value of warrants -- 510 Change in assets and liabilities: Accounts receivable (1,468) (738) Deferred subcontractor cost (746) (1,005) Prepaid and other assets (57) (31) Accounts payable and accrued expenses 1,815 (249) Deferred revenue 776 1,046 ------------- ------------- Net cash used in operating activities (349) (1,913) ------------- ------------- Cash flows provided by financing activities: Proceeds from issuance of common stock and warrants -- 3,616 Costs related to the issuance of common stock and warrants -- (58) ------------- ------------- Net cash provided by financing activities -- 3,558 ------------- ------------- Net decrease in cash and cash equivalents (349) 1,645 Cash and cash equivalents at beginning of period 869 281 ------------- ------------- Cash and cash equivalents at end of period $ 520 $ 1,926 ============= ============= Supplemental disclosure of cash flow information: State income taxes $ -- $ -- ============= =============
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
President and Chief Executive Officer
Aeolus Pharmaceuticals, Inc.
Digital innovation is the next big wave of business transformation based on digital technologies of which IoT and Big Data are key components, For example: Business boundary innovation is a challenge to excavate third-party business value using IoT and BigData, like Nest Business structure innovation may propose re-building business structure from scratch, as Uber does in the taxicab industry The social model innovation is also a big challenge to the new social architecture with the design fr...
Sep. 28, 2016 03:15 PM EDT Reads: 1,295
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
Sep. 28, 2016 03:15 PM EDT Reads: 4,123
What are the new priorities for the connected business? First: businesses need to think differently about the types of connections they will need to make – these span well beyond the traditional app to app into more modern forms of integration including SaaS integrations, mobile integrations, APIs, device integration and Big Data integration. It’s important these are unified together vs. doing them all piecemeal. Second, these types of connections need to be simple to design, adapt and configure...
Sep. 28, 2016 03:15 PM EDT Reads: 306
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, wh...
Sep. 28, 2016 03:00 PM EDT Reads: 3,857
Data is an unusual currency; it is not restricted by the same transactional limitations as money or people. In fact, the more that you leverage your data across multiple business use cases, the more valuable it becomes to the organization. And the same can be said about the organization’s analytics. In his session at 19th Cloud Expo, Bill Schmarzo, CTO for the Big Data Practice at EMC, will introduce a methodology for capturing, enriching and sharing data (and analytics) across the organizati...
Sep. 28, 2016 02:45 PM EDT Reads: 1,736
SYS-CON Events announced today that Bsquare has been named “Silver Sponsor” of SYS-CON's @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. For more than two decades, Bsquare has helped its customers extract business value from a broad array of physical assets by making them intelligent, connecting them, and using the data they generate to optimize business processes.
Sep. 28, 2016 02:30 PM EDT Reads: 2,921
SYS-CON Events has announced today that Roger Strukhoff has been named conference chair of Cloud Expo and @ThingsExpo 2016 Silicon Valley. The 19th Cloud Expo and 6th @ThingsExpo will take place on November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. "The Internet of Things brings trillions of dollars of opportunity to developers and enterprise IT, no matter how you measure it," stated Roger Strukhoff. "More importantly, it leverages the power of devices and the Interne...
Sep. 28, 2016 02:30 PM EDT Reads: 3,294
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
Sep. 28, 2016 02:00 PM EDT Reads: 4,414
We’ve been doing it for years, decades for some. How many websites have you created accounts on? Your bank, your credit card companies, social media sites, hotels and travel sites, online shopping sites, and that’s just the start. We do it often without even thinking about it, quickly entering our personal information, our data, in a plethora of systems. Sometimes we’re not even aware of the information we are providing. It could be very personal information (think of the security questions you ...
Sep. 28, 2016 02:00 PM EDT Reads: 4,752
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lea...
Sep. 28, 2016 01:57 PM EDT Reads: 200
According to Forrester Research, every business will become either a digital predator or digital prey by 2020. To avoid demise, organizations must rapidly create new sources of value in their end-to-end customer experiences. True digital predators also must break down information and process silos and extend digital transformation initiatives to empower employees with the digital resources needed to win, serve, and retain customers.
Sep. 28, 2016 01:23 PM EDT Reads: 235
Video experiences should be unique and exciting! But that doesn’t mean you need to patch all the pieces yourself. Users demand rich and engaging experiences and new ways to connect with you. But creating robust video applications at scale can be complicated, time-consuming and expensive. In his session at @ThingsExpo, Zohar Babin, Vice President of Platform, Ecosystem and Community at Kaltura, will discuss how VPaaS enables you to move fast, creating scalable video experiences that reach your...
Sep. 28, 2016 01:00 PM EDT Reads: 1,104
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life sett...
Sep. 28, 2016 01:00 PM EDT Reads: 3,547
Businesses are struggling to manage the information flow and interactions between all of these new devices and things jumping on their network, and the apps and IT systems they control. The data businesses gather is only helpful if they can do something with it. In his session at @ThingsExpo, Chris Witeck, Principal Technology Strategist at Citrix, will discuss how different the impact of IoT will be for large businesses, expanding how IoT will allow large organizations to make their legacy ap...
Sep. 28, 2016 01:00 PM EDT Reads: 166
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - comp...
Sep. 28, 2016 12:30 PM EDT Reads: 5,098